Department of Gynecologic Oncology (5), Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
J Obstet Gynaecol Res. 2022 Dec;48(12):3171-3178. doi: 10.1111/jog.15439. Epub 2022 Sep 29.
Cervical cancer has attracted increasing attention in recent years, and the incidence has shown a trend of younger age. Therefore, it is an effective method to regulate the progression of cervical cancer through new prognostic biomarkers. The purpose of this study was to evaluate the potential of lncRNA LAMTOR5-AS1 (LAMTOR5-AS1) as a prognostic biomarker and reveal its regulatory role in cervical cancer.
A total of 120 patients with cervical cancer were selected as research subjects to verify the prognostic effect of LAMTOR5-AS1 in a series of experiments. The expression of LAMTOR5-AS1 in cervical cancer tissues and cells was determined by polymerase chain reaction assay. The proliferation, migration, and invasion ability of cervical cancer cells were evaluated by Cell Counting Kit-8 (CCK-8) and Transwell assay. Luciferase reporter gene detection was used to determine the mechanism of LAMTOR5-AS1 targeting miR-210-3p, and to reflect the prognostic value of LAMTOR5-AS1 according to statistical methods.
LAMTOR5-AS1 decreased in cervical cancer tissues, while miR-210-3p expression increased. In the study of cervical cancer cells, it was found that the LAMTOR5-AS1 sponge miR-210-3p was associated with the malignant progression of cervical cancer. Overexpression of LAMTOR5-AS1 could effectively inhibit the development of cervical cancer cells and might be chosen as a prognostic biomarker of cervical cancer.
LAMTOR5-AS1 sponges miR-210-3p and modulates the progression of cervical cancer, which predict the prognosis of cervical cancer patients.
近年来,宫颈癌受到了越来越多的关注,其发病率呈年轻化趋势。因此,通过新的预后生物标志物来调节宫颈癌的进展是一种有效的方法。本研究旨在评估长亮氨酸重复序列 5-反义 RNA(LAMTOR5-AS1)作为预后生物标志物的潜力,并揭示其在宫颈癌中的调控作用。
选取 120 例宫颈癌患者作为研究对象,通过一系列实验验证 LAMTOR5-AS1 在宫颈癌中的预后作用。采用聚合酶链反应检测宫颈癌组织和细胞中 LAMTOR5-AS1 的表达。通过细胞计数试剂盒-8(CCK-8)和 Transwell 实验评估宫颈癌细胞的增殖、迁移和侵袭能力。采用荧光素酶报告基因检测确定 LAMTOR5-AS1 靶向 miR-210-3p 的机制,并通过统计方法反映 LAMTOR5-AS1 的预后价值。
LAMTOR5-AS1 在宫颈癌组织中降低,而 miR-210-3p 表达增加。在宫颈癌细胞的研究中发现,LAMTOR5-AS1 海绵 miR-210-3p 与宫颈癌的恶性进展有关。LAMTOR5-AS1 的过表达可有效抑制宫颈癌细胞的发展,可能作为宫颈癌的预后生物标志物。
LAMTOR5-AS1 海绵 miR-210-3p 并调节宫颈癌的进展,可预测宫颈癌患者的预后。